Guilford Gliadel Wafer review rescheduled
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA Oncologic Drugs Advisory Committee will review Guilford's Gliadel Wafer for malignant glioma Dec. 6. The review, originally slated for Sept. 11, was rescheduled from Dec. 4